Izun Pharmaceuticals Initiates Additional Oral Mucositis Trial Sites

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Izun Pharmaceuticals Corporation. (“Izun”, www.izunpharma.com), an emerging pharmaceutical company focusing on developing botanical drugs announced today that it has expanded its ongoing Phase II trial assessing the effect of its novel drug candidate, IZN-6N4, on Oral Mucositis (“OM”) to two additional medical centers, Memorial Sloan Kettering Cancer Center and Beth Israel Medical Center, a component of the Continuum Cancer Centers of New York. The studies are evaluating the onset and incidence of OM in head and neck cancer patients undergoing chemo and radiation therapy (CRT). OM is a frequent and severe side effect that develops as a result of CRT. It is a painful and ulcerated inflammation of the oral mucosa and impacts significantly on the quality of life of cancer patients. In severe cases, the CRT has to be modulated or discontinued due to the OM and impact negatively on the success of the treatment regimen.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC